Cell-based Immunotherapy Against Gliomas: From Bench to Bedside

Glioblastoma (GBM) comprises 51% of all gliomas and is the most malignant form of brain tumors with a median survival of 18–21 months. Standard-of-care treatment includes maximal surgical resection of the tumor mass in combination with radiation and chemotherapy. However, as the poor survival rate i...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Bovenberg, M Sarah S, Degeling, M Hannah, Tannous, Bakhos A
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2013
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3702108/
https://ncbi.nlm.nih.gov/pubmed/23648695
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2013.80
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller